title: Weight loss significantly reduces serum lipocalin-2 levels in overweight and obese women with polycystic ovary syndrome.
abstract: Serum lipocalin-2 levels are elevated in obese patients. We assessed serum lipocalin-2 levels in polycystic ovary syndrome (PCOS) and the effects of weight loss or metformin on these levels. Forty-seven overweight/obese patients with PCOS [body mass index (BMI) >27 kg/m(2)] were instructed to follow a low-calorie diet, to exercise and were given orlistat or sibutramine for 6 months. Twenty-five normal weight patients with PCOS (BMI <25 kg/m(2)) were treated with metformin for 6 months. Twenty-five normal weight and 25 overweight/obese healthy female volunteers comprised the control groups. Serum lipocalin-2 levels did not differ between overweight/obese patients with PCOS and overweight/obese controls (p = 0.258), or between normal weight patients with PCOS and normal weight controls (p = 0.878). Lipocalin-2 levels were higher in overweight/obese patients with PCOS than in normal weight patients with PCOS (p < 0.001). In overweight/obese patients with PCOS, weight loss resulted in a fall in lipocalin-2 levels (p < 0.001). In normal weight patients with PCOS, treatment with metformin did not affect lipocalin-2 levels (p = 0.484). In conclusion, PCOS per se is not associated with elevated lipocalin-2 levels. Weight loss induces a significant reduction in lipocalin-2 levels in overweight/obese patients with PCOS.
authors.affiliation: Division of Endocrinology and Human Reproduction, Second Department of Obstetrics and Gynecology, Aristotle University of Thessaloniki, Hippokration Hospital, Thessaloniki, Greece.
authors.forename: Ekaterini
authors.initials: E
authors.lastname: Koiou
authors.forename: Konstantinos
authors.initials: K
authors.lastname: Tziomalos
authors.forename: Ilias
authors.initials: I
authors.lastname: Katsikis
authors.forename: Eleni A
authors.initials: EA
authors.lastname: Kandaraki
authors.forename: Emmanuil
authors.initials: E
authors.lastname: Kalaitzakis
authors.forename: Dimitrios
authors.initials: D
authors.lastname: Delkos
authors.forename: Christos
authors.initials: C
authors.lastname: Vosnakis
authors.forename: Dimitrios
authors.initials: D
authors.lastname: Panidis
mesh_terms: D000209:Acute-Phase Proteins; D000293:Adolescent; D000328:Adult; D019440:Anti-Obesity Agents / Q000627:therapeutic use; D031204:Caloric Restriction; D003131:Combined Modality Therapy; D003503:Cyclobutanes / Q000627:therapeutic use; D015536:Down-Regulation; D005081:Exercise Therapy; D005260:Female; D006801:Humans; D007783:Lactones / Q000627:therapeutic use; D000071068:Lipocalin-2; D054834:Lipocalins / Q000097:blood*; D008687:Metformin / Q000627:therapeutic use; D009765:Obesity / Q000097:blood* / Q000150:complications / Q000628:therapy; D000077403:Orlistat; D050177:Overweight / Q000097:blood* / Q000150:complications / Q000628:therapy; D011085:Polycystic Ovary Syndrome / Q000097:blood* / Q000150:complications / Q000628:therapy; D011518:Proto-Oncogene Proteins / Q000097:blood*; D015431:Weight Loss / Q000502:physiology*; D055815:Young Adult
chemical_list: D000209:Acute-Phase Proteins; D019440:Anti-Obesity Agents; D003503:Cyclobutanes; C489506:LCN2 protein, human; D007783:Lactones; D000071068:Lipocalin-2; D054834:Lipocalins; D011518:Proto-Oncogene Proteins; D008687:Metformin; D000077403:Orlistat; C058254:sibutramine